UK Infectious Disease Drugs Market Analysis Report 2022 to 2030

UK Infectious Disease Drugs Market Analysis

$ 3999

UK Infectious Disease Drugs Market valued at $3.08 Bn in 2023, projected to reach $3.61 Bn by 2030 with a 2.27% CAGR. Rising antimicrobial resistance, technological advancements, government initiatives, and funding are some of the factors driving the market. The market is dominated by key players like GlaxoSmithKline plc, AstraZeneca, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, and Sanofi S.A.

ID: IN10GBPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Aneri Parekh

Buy Now

UK Infectious Disease Drugs Market Executive Summary

UK Infectious Disease Drugs Market valued at $3.08 Bn in 2023, projected to reach $3.61 Bn by 2030 with a 2.27% CAGR.

The development, production, and distribution of pharmaceuticals to treat infectious diseases in the United Kingdom is the primary goal of the infectious disease drugs market in the country. This market includes a broad spectrum of medications, such as antibiotics, antivirals, antifungals, and antiparasitic medications, that target bacterial, viral, fungal, and parasitic illnesses. Within the UK healthcare sector, factors like changing pathogens, antibiotic resistance, and public health initiatives impact this market's growth and dynamics.

Increases in the prevalence of infectious diseases and improvements in drug development are driving the UK's infectious disease drugs market's steady growth. Major players in the market are concentrating on R&D efforts to introduce novel therapies and vaccines to address emerging infectious diseases, and government initiatives aimed at controlling infectious diseases and promoting public health are also fueling market growth.

The global market for pharmaceuticals treating infectious diseases was estimated at $118.75 Bn in 2023. This expansion is attributed to both the increase in diagnoses and government-sponsored public education campaigns regarding the management and prevention of infectious diseases. A shifting market environment is indicated by the growing degree of generic competition. Increasing treatment accessibility and reducing financial barriers are essential for long-term development, particularly in developing countries. This will encourage more industry research and development.

Leading pharmaceutical business GlaxoSmithKline plc (GSK) has its headquarters in the UK. GSK makes significant investments in research and development (R&D) for novel vaccines and therapies as it views infectious diseases as a core therapeutic area. Their pipeline is almost entirely devoted to infectious disorders. In the UK, they provide a range of vaccinations, such as those for meningitis and shingles in addition to regular childhood immunizations against other infectious diseases. Additionally, GSK offers several drugs in the UK to treat respiratory conditions and infectious diseases including HIV.

UK infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Growing Concern over Antimicrobial Resistance: Antimicrobial resistance, or AMR, is becoming a big issue in the UK. The development of novel medications and treatment approaches is required due to the proliferation of drug-resistant bacteria and viruses, driving the market toward growth.

Technological Developments: The creation of more precise and potent treatments for infectious diseases is made possible by developments in molecular biology, genomics, and drug discovery.

Government Initiatives and Funding: The UK funds academic institutions, pharmaceutical firms, and public health organizations and invests in research and development projects to prevent infectious diseases. These programs promote the commercialization of novel medications and foster innovation in the industry.

Market Restraints:

Regulatory Hurdles: The UK market for medications for infectious diseases may not grow as quickly as it could due to strict laws and drawn-out approval procedures for new medications.

Pricing Pressures: Pharmaceutical businesses may face pressure to lower their prices as a result of the National Health Service (NHS) in the UK operating under strict budgetary limits.

Generic Competition: Branded medications are susceptible to competition from generic counterparts once their patents expire. Since generic medications are usually less expensive than branded ones, branded infectious illness medications may lose market share in the UK.

Healthcare Policies and Regulatory Landscape

Medical equipment, medications, and blood components are regulated in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). The executive agency known as MHRA is sponsored by the Department of Health and Social Care. The regulatory agency reviews clinical research to make sure the drug is safe, effective, and meets manufacturing quality standards. If they are satisfied, a license or marketing authorization is given. This enables the license holder to offer the product for sale in the regions under the regulatory body's jurisdiction. There are thorough regulatory evaluations, extensive clinical investigations, and adherence to the MHRA's stringent safety and efficacy requirements. It takes a lot of time and resources to complete these processes, which occasionally results in delays and challenges when new drugs are introduced to the market.

Competitive Landscape

Key Players:

GlaxoSmithKline plc
AstraZeneca
AbbVie Inc.
Gilead Sciences
Merck & Co.
F. Hoffman-La Roche Ltd.
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG
Sanofi S.A.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.